Inventor
MASCOLA JOHN
US41 patents
⚠️ This page may combine multiple inventors who share the name “MASCOLA JOHN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
US HEALTH
32 patentsUS10301377B2May 28, 2019
Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
US HEALTH24 citations93
US10961283B2Mar 30, 2021
Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens
US HEALTH11 citations83
US10035844B2Jul 31, 2018
Broadly neutralizing HIV-1 VRC07 antibodies that bind to the CD4-binding site of the envelope protein
US HEALTH6 citations83
US9695230B2Jul 4, 2017
Broadly neutralizing HIV-1 VRC07 antibodies that bind to the CD4-binding site of the envelope protein
US HEALTH9 citations83
US10400015B2Sep 3, 2019
Recombinant HIV-1 envelope proteins and their use
US HEALTH10 citations82
US10562960B2Feb 18, 2020
Neutralizing antibodies to gp120 and their use
US HEALTH5 citations81
US11760790B2Sep 19, 2023
Neutralizing antibodies to HIV-1 Env and their use
US HEALTH2 citations72
US11602559B2Mar 14, 2023
HIV-1 Env fusion peptide immunogens and their use
US HEALTH2 citations72
US11078239B2Aug 3, 2021
Prefusion PIV F immunogens and their use
US HEALTH1 citations72
US10035845B2Jul 31, 2018
Neutralizing antibodies to HIV-1 and their use
US HEALTH2 citations72
US9738703B2Aug 22, 2017
Neutralizing antibodies to HIV-1 and their use
US HEALTH2 citations72
US12202886B2Jan 21, 2025
Neutralizing antibodies to GP120 and their use
US HEALTH1 citations71
US11939356B2Mar 26, 2024
Self-assembling insect ferritin nanoparticles
US HEALTH2 citations71
US11890339B2Feb 6, 2024
Nipah virus immunogens and their use
US HEALTH2 citations71
US11878998B2Jan 23, 2024
Prefusion RSV F proteins and their use
US HEALTH2 citations71
US11459360B2Oct 4, 2022
Recombinant HIV-1 envelope proteins and their use
US HEALTH4 citations71
US11174292B2Nov 16, 2021
Substitutions-modified prefusion RSV F proteins and their use
US HEALTH2 citations71
US12458691B2Nov 4, 2025
HIV-1 ENV fusion peptide immunogens and their use
US HEALTH0 citations62
US12435113B2Oct 7, 2025
Prefusion PIV F immunogens and their use
US HEALTH0 citations62
US11845778B2Dec 19, 2023
Prefusion PIV F immunogens and their use
US HEALTH0 citations62
US12145968B2Nov 19, 2024
Recombinant HIV-1 envelope proteins and their use
US HEALTH0 citations61
US11136356B2Oct 5, 2021
Recombinant HIV-1 envelope proteins and their use
US HEALTH0 citations61
US12275758B2Apr 15, 2025
Prefusion RSV F proteins and their use
US HEALTH0 citations60
US12545719B2Feb 10, 2026
Neutralizing antibodies to GP120 and their use
US HEALTH0 citations59
US12053519B2Aug 6, 2024
HIV-1 Env fusion peptide nanoparticle carrier conjugates and their use
US HEALTH0 citations59
US12043660B2Jul 23, 2024
10E8 neutralizing antibody variants that bind to the MPER region of HIV-1 GP41 and their use
US HEALTH0 citations56
US11236152B2Feb 1, 2022
Neutralizing antibodies to HIV-1 GP41 and their use
US HEALTH0 citations56
US10815295B2Oct 27, 2020
Broadly neutralizing HIV-1 antibodies that bind to the CD4-binding site of the envelope protein
US HEALTH0 citations51
US10759846B2Sep 1, 2020
Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
US HEALTH0 citations51
US10519222B2Dec 31, 2019
Broadly neutralizing monoclonal antibodies against HIV-1 V1V2 Env region
US HEALTH1 citations48
US8044185B2Oct 25, 2011
Conformationally stabilized HIV envelope immunogens and triggering HIV-I envelope to reveal cryptic V3-loop epitopes
US HEALTH0 citations48
US10047147B2Aug 14, 2018
Neutralizing GP41 antibodies and their use
US HEALTH0 citations44